肝肾综合征研究进展  

Research progress on hepatorenal syndrome

作　　者：熊号峰[1] 刘景院[1] 

机构地区：[1]首都医科大学附属北京地坛医院重症医学科,北京100015

出　　处：《中国肝脏病杂志（电子版）》2017年第1期1-6,共6页Chinese Journal of Liver Diseases：Electronic Version

基　　金：北京市医管局市属医院科研培育计划(PX2017019);国家"十二五"科技重大专项(2012ZX10004301-002)

摘　　要：肝肾综合征(hepatorenal syndrome,HRS)是发生在肝硬化腹水、急性肝衰竭或酒精性肝炎患者的一种严重并发症。主要发病机制为外周和内脏动脉舒张、心排量下降以及肾脏动脉收缩。国际腹水俱乐部(International Club of Ascites,ICA)在2015年制定了肝肾综合征-急性肾功能损伤诊断标准,为肝肾综合征的早期诊断和早期干预提供了新的临床路径。目前研究表明,特利加压素和白蛋白为标准治疗方案,去甲肾上腺素联合白蛋白为次选方案。预防感染及避免使用肾毒性药物等可以预防HRS的发生。Hepatorenal syndrome is a serious complication which occurs in patients with cirrhosis, acute liver failure or alcoholic hepatitis. The main pathogenesis is peripheral and visceral arteries, decreased cardiac output and renal arteries. International Club of Ascites （ICA） has developed the diagnostic criteria for hepatorenal syndrome-acute renal injury in 2015, which provided a new clinical pathway for early diagnosis and intervention. Recent studies showed that terlipressin and albumin is the standard treatment regimen and norepinephrine combined with albumin is the second best solution. To prevent infection and avoid the use of nephrotoxic drugs can prevent the occurrence of HRS.

关 键 词：肝肾综合征 肝硬化 肝功能衰竭 急性 肾功能损伤 急性 研究进展 

分 类 号：R575[医药卫生—消化系统]